Their last 2 raises of past 2 years were done @ $2.50 and $2.75 per share respectively...and they only raised $5M last year to cover their approx $1M quarterly burn rate because their mgmt team are extremely frugal with their shares!
Call them up and offer to give them funding...they won't take it and won't even entertain funding offers from anyone other than firms like Roth or Piper Jaffrey because they know better than anyone that their pending FDA approval of FocalinXR instantly transforms them to profitability...and with the pending FDA approval of FocalinXR they'll also be in a much better position of power to command MUCH MORE VALUE out of the licensing/partnership agreements they secure on their next 2 ANDA's immediately following FocalinXR.
So to address your concern of them having to go to market again for another raise b4 all the hoopla begins...even if they do go to market again with Roth or Piper Jaffrey...IMO it would only be a tiny raise with barely any discount(last 2 raises were only -5%)...and of course any small raise they did do would be done with 6 month restricted shares.
Your best bet is to call Shameze the CFO and hear it from the horses mouth how much their committed to preserving their capital structure and creating massive shareholder value over these next several years not diluting it glty
News 
Market Data 
Discover 
